speb/financial-data huggingface dataset:
TCBIO cash_flow (annual, 2023-12-31) — Cash Flow From Continuing Operating Activities: 373740000.00
TCBIO cash_flow (annual, 2023-12-31) — Change In Account Payable: 29134000.00
TCBIO cash_flow (annual, 2023-12-31) — Change In Payable: 29134000.00
TCBIO cash_flow (annual, 2023-12-31) — Change In Payables And Accrued Expense: 29134000.00
TCBIO cash_flow (annual, 2023-12-31) — Change In Receivables: -78606000.00
TCBIO cash_flow (annual, 2023-12-31) — Change In Working Capital: -49472000.00
TCBIO cash_flow (annual, 2023-12-31) — Changes In Account Receivables: -78606000.00
TCBIO cash_flow (annual, 2023-12-31) — Changes In Cash: -1769410000.00
TCBIO balance_sheet (annual, 2023-12-31) — Common Stock: 511000.00
TCBIO balance_sheet (annual, 2023-12-31) — Common Stock Equity: 2899142000.00
TCBIO cash_flow (annual, 2023-12-31) — Common Stock Payments: -105024000.00
TCBIO balance_sheet (annual, 2023-12-31) — Current Debt: 1500000000.00
TCBIO balance_sheet (annual, 2023-12-31) — Current Debt And Capital Lease Obligation: 1500000000.00
TCBIO cash_flow (annual, 2023-12-31) — Deferred Income Tax: -17784000.00
TCBIO cash_flow (annual, 2023-12-31) — Deferred Tax: -17784000.00
TCBIO cash_flow (annual, 2023-12-31) — Depreciation Amortization Depletion: 40473000.00
TCBIO cash_flow (annual, 2023-12-31) — Depreciation And Amortization: 40473000.00
TCBIO income_statement (annual, 2023-12-31) — Diluted NI Availto Com Stockholders: 171891000.00
TCBIO cash_flow (annual, 2023-12-31) — End Cash Position: 3242850000.00
TCBIO cash_flow (annual, 2023-12-31) — Financing Cash Flow: -387672000.00
TCBIO cash_flow (annual, 2023-12-31) — Free Cash Flow: 357359000.00
TCBIO cash_flow (annual, 2023-12-31) — Gain Loss On Investment Securities: -3571000.00
TCBIO cash_flow (annual, 2023-12-31) — Gain Loss On Sale Of Business: 0.00
TCBIO income_statement (annual, 2023-12-31) — Gain On Sale Of Business: 0.00
TCBIO income_statement (annual, 2023-12-31) — Gain On Sale Of Security: 489000.00
TCBIO balance_sheet (annual, 2023-12-31) — Gains Losses Not Affecting Retained Earnings: -362004000.00
TCBIO income_statement (annual, 2023-12-31) — General And Administrative Expense: 496475000.00
TCBIO balance_sheet (annual, 2023-12-31) — Goodwill And Other Intangible Assets: 1496000.00
TCBIO balance_sheet (annual, 2023-12-31) — Gross PPE: 102914000.00
TCBIO balance_sheet (annual, 2023-12-31) — Held To Maturity Securities: 865477000.00
TCBIO cash_flow (annual, 2023-12-31) — Income Tax Paid Supplemental Data: 71941000.00
TCBIO income_statement (annual, 2023-12-31) — Insurance And Claims: 36775000.00
TCBIO income_statement (annual, 2023-12-31) — Interest Expense: 715800000.00
TCBIO income_statement (annual, 2023-12-31) — Interest Income: 1629923000.00
TCBIO cash_flow (annual, 2023-12-31) — Interest Paid Supplemental Data: 773034000.00
TCBIO balance_sheet (annual, 2023-12-31) — Invested Capital: 5258289000.00
TCBIO cash_flow (annual, 2023-12-31) — Investing Cash Flow: -1755478000.00
TCBIO balance_sheet (annual, 2023-12-31) — Investments And Advances: 4143194000.00
TCBIO cash_flow (annual, 2023-12-31) — Issuance Of Capital Stock: 0.00
TCBIO cash_flow (annual, 2023-12-31) — Issuance Of Debt: 0.00
TCBIO balance_sheet (annual, 2023-12-31) — Long Term Debt: 859147000.00
TCBIO balance_sheet (annual, 2023-12-31) — Long Term Debt And Capital Lease Obligation: 859147000.00
TCBIO cash_flow (annual, 2023-12-31) — Long Term Debt Issuance: 0.00
TCBIO cash_flow (annual, 2023-12-31) — Long Term Debt Payments: -75000000.00
TCBIO balance_sheet (annual, 2023-12-31) — Machinery Furniture Equipment: 63367000.00
TCBIO cash_flow (annual, 2023-12-31) — Net Business Purchase And Sale: 0.00
TCBIO cash_flow (annual, 2023-12-31) — Net Common Stock Issuance: -105024000.00
TCBIO income_statement (annual, 2023-12-31) — Net Income: 189141000.00
TCBIO income_statement (annual, 2023-12-31) — Net Income Common Stockholders: 171891000.00
TCBIO income_statement (annual, 2023-12-31) — Net Income Continuous Operations: 189141000.00
TCBIO income_statement (annual, 2023-12-31) — Net Income From Continuing And Discontinued Operation: 189141000.00
TCBIO income_statement (annual, 2023-12-31) — Net Income From Continuing Operation Net Minority Interest: 189141000.00
TCBIO cash_flow (annual, 2023-12-31) — Net Income From Continuing Operations: 189141000.00
TCBIO income_statement (annual, 2023-12-31) — Net Income Including Noncontrolling Interests: 189141000.00
TCBIO cash_flow (annual, 2023-12-31) — Net Intangibles Purchase And Sale: 0.00
TCBIO income_statement (annual, 2023-12-31) — Net Interest Income: 914123000.00
TCBIO cash_flow (annual, 2023-12-31) — Net Investment Purchase And Sale: -507962000.00
TCBIO cash_flow (annual, 2023-12-31) — Net Issuance Payments Of Debt: 223858000.00
TCBIO cash_flow (annual, 2023-12-31) — Net Long Term Debt Issuance: -75000000.00
TCBIO balance_sheet (annual, 2023-12-31) — Net PPE: 32366000.00
TCBIO cash_flow (annual, 2023-12-31) — Net PPE Purchase And Sale: -16381000.00
TCBIO cash_flow (annual, 2023-12-31) — Net Preferred Stock Issuance: 0.00
TCBIO cash_flow (annual, 2023-12-31) — Net Short Term Debt Issuance: 298858000.00
TCBIO balance_sheet (annual, 2023-12-31) — Net Tangible Assets: 3197646000.00
TCBIO income_statement (annual, 2023-12-31) — Normalized Income: 189141000.00
TCBIO income_statement (annual, 2023-12-31) — Occupancy And Equipment: 38494000.00
TCBIO cash_flow (annual, 2023-12-31) — Operating Cash Flow: 373740000.00
TCBIO cash_flow (annual, 2023-12-31) — Operating Gains Losses: -4060000.00
TCBIO income_statement (annual, 2023-12-31) — Operating Revenue: 1075542000.00
TCBIO balance_sheet (annual, 2023-12-31) — Ordinary Shares Number: 47237912.00
TCBIO balance_sheet (annual, 2023-12-31) — Other Current Borrowings: 1500000000.00
TCBIO balance_sheet (annual, 2023-12-31) — Other Equity Adjustments: -362004000.00
TCBIO cash_flow (annual, 2023-12-31) — Other Non Cash Items: 119242000.00
TCBIO income_statement (annual, 2023-12-31) — Other Non Interest Expense: 131200000.00
TCBIO balance_sheet (annual, 2023-12-31) — Other Short Term Investments: 3225892000.00
TCBIO balance_sheet (annual, 2023-12-31) — Payables: 33234000.00
TCBIO balance_sheet (annual, 2023-12-31) — Payables And Accrued Expenses: 33234000.00
TCBIO balance_sheet (annual, 2023-12-31) — Preferred Shares Number: 300000.00
TCBIO balance_sheet (annual, 2023-12-31) — Preferred Stock: 300000000.00
TCBIO cash_flow (annual, 2023-12-31) — Preferred Stock Dividend Paid: -17250000.00
TCBIO income_statement (annual, 2023-12-31) — Preferred Stock Dividends: 17250000.00
TCBIO balance_sheet (annual, 2023-12-31) — Preferred Stock Equity: 300000000.00
TCBIO cash_flow (annual, 2023-12-31) — Preferred Stock Issuance: 0.00
TCBIO cash_flow (annual, 2023-12-31) — Preferred Stock Payments: 0.00
TCBIO income_statement (annual, 2023-12-31) — Pretax Income: 246595000.00
TCBIO cash_flow (annual, 2023-12-31) — Proceeds From Stock Option Exercised: -4215000.00
TCBIO income_statement (annual, 2023-12-31) — Professional Expense And Contract Services Expense: 64924000.00
TCBIO balance_sheet (annual, 2023-12-31) — Properties: 39547000.00
TCBIO cash_flow (annual, 2023-12-31) — Purchase Of Investment: -863689000.00
TCBIO cash_flow (annual, 2023-12-31) — Purchase Of PPE: -16381000.00
TCBIO balance_sheet (annual, 2023-12-31) — Receivables: 801670000.00
TCBIO income_statement (annual, 2023-12-31) — Reconciled Depreciation: 40473000.00
TCBIO cash_flow (annual, 2023-12-31) — Repayment Of Debt: -75000000.00
TCBIO cash_flow (annual, 2023-12-31) — Repurchase Of Capital Stock: -105024000.00
TCBIO balance_sheet (annual, 2023-12-31) — Retained Earnings: 2435393000.00
TCBIO income_statement (annual, 2023-12-31) — Salaries And Wages: 459700000.00
TCBIO cash_flow (annual, 2023-12-31) — Sale Of Business: 0.00
TCBIO cash_flow (annual, 2023-12-31) — Sale Of Intangibles: 0.00
TCBIO cash_flow (annual, 2023-12-31) — Sale Of Investment: 355727000.00
TCBIO income_statement (annual, 2023-12-31) — Selling And Marketing Expense: 25854000.00
TCBIO income_statement (annual, 2023-12-31) — Selling General And Administration: 522329000.00
TCBIO balance_sheet (annual, 2023-12-31) — Share Issued: 51142979.00
TCBIO income_statement (annual, 2023-12-31) — Special Income Charges: 0.00
TCBIO cash_flow (annual, 2023-12-31) — Stock Based Compensation: 24200000.00
TCBIO balance_sheet (annual, 2023-12-31) — Stockholders Equity: 3199142000.00
TCBIO balance_sheet (annual, 2023-12-31) — Tangible Book Value: 2897646000.00
TCBIO income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: 0.00
TCBIO income_statement (annual, 2023-12-31) — Tax Provision: 57454000.00
TCBIO income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.23
TCBIO balance_sheet (annual, 2023-12-31) — Total Assets: 28356266000.00
TCBIO balance_sheet (annual, 2023-12-31) — Total Capitalization: 4058289000.00
TCBIO balance_sheet (annual, 2023-12-31) — Total Debt: 2359147000.00
TCBIO balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 3199142000.00
TCBIO balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 25157124000.00
TCBIO income_statement (annual, 2023-12-31) — Total Unusual Items: 0.00
TCBIO income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: 0.00
TCBIO balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 3905067.00
TCBIO balance_sheet (annual, 2023-12-31) — Treasury Stock: 220334000.00
TCBIO cash_flow (quarterly, 2024-09-30) — Income Tax Paid Supplemental Data: 52000.00
TCBIO cash_flow (quarterly, 2024-09-30) — Other Non Cash Items: 27763000.00
TCBIO income_statement (annual, 2024-12-31) — +Total Revenue: 932346000.00
TCBIO balance_sheet (annual, 2024-12-31) — Accounts Payable: 23680000.00
TCBIO balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -36112000.00
TCBIO balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -36112000.00
TCBIO balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 1056719000.00
TCBIO balance_sheet (annual, 2024-12-31) — Available For Sale Securities: 75261000.00
TCBIO cash_flow (annual, 2024-12-31) — Beginning Cash Position: 3242850000.00
TCBIO cash_flow (annual, 2024-12-31) — Capital Expenditure: -64841000.00
TCBIO cash_flow (quarterly, 2024-12-31) — Capital Expenditure: -7406000.00
TCBIO balance_sheet (annual, 2024-12-31) — Capital Stock: 300515000.00
TCBIO balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 3188808000.00
TCBIO balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Federal Funds Sold: 3188808000.00
TCBIO cash_flow (annual, 2024-12-31) — Cash Dividends Paid: -17250000.00
TCBIO balance_sheet (annual, 2024-12-31) — Cash Financial: 176501000.00
TCBIO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: 1943937000.00
TCBIO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -2478067000.00
TCBIO cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 480088000.00
TCBIO cash_flow (annual, 2024-12-31) — Change In Account Payable: 38878000.00
TCBIO cash_flow (annual, 2024-12-31) — Change In Payable: 38878000.00
TCBIO cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: 38878000.00
TCBIO cash_flow (annual, 2024-12-31) — Change In Receivables: -1611000.00
TCBIO cash_flow (annual, 2024-12-31) — Change In Working Capital: 37267000.00
TCBIO cash_flow (annual, 2024-12-31) — Changes In Account Receivables: -1611000.00
TCBIO cash_flow (annual, 2024-12-31) — Changes In Cash: -54042000.00
TCBIO balance_sheet (annual, 2024-12-31) — Common Stock: 515000.00
TCBIO balance_sheet (annual, 2024-12-31) — Common Stock Equity: 3067936000.00
TCBIO cash_flow (annual, 2024-12-31) — Common Stock Payments: -81508000.00
TCBIO balance_sheet (annual, 2024-12-31) — Current Debt: 885000000.00
TCBIO balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 885000000.00
TCBIO cash_flow (annual, 2024-12-31) — Deferred Income Tax: -16086000.00
TCBIO cash_flow (annual, 2024-12-31) — Deferred Tax: -16086000.00
TCBIO cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 54228000.00
TCBIO cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 54228000.00
TCBIO income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: 60258000.00
TCBIO cash_flow (annual, 2024-12-31) — End Cash Position: 3188808000.00
TCBIO cash_flow (annual, 2024-12-31) — Financing Cash Flow: 1943937000.00
TCBIO cash_flow (annual, 2024-12-31) — Free Cash Flow: 415247000.00
TCBIO cash_flow (annual, 2024-12-31) — Gain Loss On Investment Securities: -6619000.00
TCBIO cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of Business: 0.00
TCBIO income_statement (annual, 2024-12-31) — Gain On Sale Of Business: 0.00
TCBIO income_statement (annual, 2024-12-31) — Gain On Sale Of Security: -179581000.00
TCBIO balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -183107000.00
TCBIO income_statement (annual, 2024-12-31) — General And Administrative Expense: 489929000.00
TCBIO balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 1496000.00
TCBIO balance_sheet (annual, 2024-12-31) — Gross PPE: 121555000.00
TCBIO balance_sheet (quarterly, 2024-12-31) — Gross PPE: 121555000.00
TCBIO balance_sheet (annual, 2024-12-31) — Held To Maturity Securities: 796168000.00
TCBIO cash_flow (annual, 2024-12-31) — Income Tax Paid Supplemental Data: 52815000.00
TCBIO cash_flow (quarterly, 2024-12-31) — Income Tax Paid Supplemental Data: 4775000.00
TCBIO income_statement (annual, 2024-12-31) — Insurance And Claims: 23351000.00
TCBIO income_statement (annual, 2024-12-31) — Interest Expense: 828250000.00
TCBIO income_statement (annual, 2024-12-31) — Interest Income: 1729550000.00
TCBIO cash_flow (annual, 2024-12-31) — Interest Paid Supplemental Data: 837804000.00
TCBIO balance_sheet (annual, 2024-12-31) — Invested Capital: 4613282000.00
TCBIO cash_flow (annual, 2024-12-31) — Investing Cash Flow: -2478067000.00
TCBIO balance_sheet (annual, 2024-12-31) — Investments And Advances: 4396115000.00
TCBIO balance_sheet (annual, 2024-12-31) — Long Term Debt: 660346000.00
TCBIO balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 660346000.00
TCBIO cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -200000000.00
TCBIO balance_sheet (annual, 2024-12-31) — Machinery Furniture Equipment: 47327000.00
TCBIO balance_sheet (quarterly, 2024-12-31) — Machinery Furniture Equipment: 47327000.00
TCBIO cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 0.00
TCBIO cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -81508000.00
TCBIO income_statement (annual, 2024-12-31) — Net Income: 77508000.00
TCBIO income_statement (annual, 2024-12-31) — Net Income Common Stockholders: 60258000.00
TCBIO income_statement (annual, 2024-12-31) — Net Income Continuous Operations: 77508000.00
TCBIO income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 77508000.00
TCBIO income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 77508000.00
TCBIO cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: 77508000.00
TCBIO income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: 77508000.00
TCBIO income_statement (annual, 2024-12-31) — Net Interest Income: 901300000.00
TCBIO cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: -247013000.00
TCBIO cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -815000000.00
TCBIO cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -200000000.00
TCBIO balance_sheet (annual, 2024-12-31) — Net PPE: 85443000.00
TCBIO cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -64841000.00
TCBIO cash_flow (annual, 2024-12-31) — Net Short Term Debt Issuance: -615000000.00
TCBIO balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 3366440000.00
TCBIO income_statement (annual, 2024-12-31) — Normalized Income: 77508000.00
TCBIO income_statement (annual, 2024-12-31) — Occupancy And Equipment: 45266000.00
TCBIO cash_flow (annual, 2024-12-31) — Operating Cash Flow: 480088000.00
TCBIO cash_flow (annual, 2024-12-31) — Operating Gains Losses: 172962000.00
TCBIO income_statement (annual, 2024-12-31) — Operating Revenue: 932346000.00
TCBIO balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 46233812.00
TCBIO balance_sheet (annual, 2024-12-31) — Other Current Borrowings: 885000000.00
TCBIO balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -183107000.00
TCBIO cash_flow (annual, 2024-12-31) — Other Non Cash Items: 62516000.00
TCBIO cash_flow (quarterly, 2024-12-31) — Other Non Cash Items: 9022000.00
TCBIO income_statement (annual, 2024-12-31) — Other Non Interest Expense: 146958000.00
TCBIO balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 3524686000.00
TCBIO balance_sheet (annual, 2024-12-31) — Payables: 23680000.00
TCBIO balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 23680000.00
TCBIO balance_sheet (annual, 2024-12-31) — Preferred Shares Number: 300000.00
TCBIO balance_sheet (annual, 2024-12-31) — Preferred Stock: 300000000.00
TCBIO cash_flow (annual, 2024-12-31) — Preferred Stock Dividend Paid: -17250000.00
TCBIO income_statement (annual, 2024-12-31) — Preferred Stock Dividends: 17250000.00
TCBIO balance_sheet (annual, 2024-12-31) — Preferred Stock Equity: 300000000.00
TCBIO income_statement (annual, 2024-12-31) — Pretax Income: 107061000.00
TCBIO cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: -9065000.00
TCBIO income_statement (annual, 2024-12-31) — Professional Expense And Contract Services Expense: 53783000.00
TCBIO balance_sheet (annual, 2024-12-31) — Properties: 74228000.00
TCBIO balance_sheet (quarterly, 2024-12-31) — Properties: 74228000.00
TCBIO cash_flow (annual, 2024-12-31) — Purchase Of Investment: -2015890000.00
TCBIO cash_flow (annual, 2024-12-31) — Purchase Of PPE: -64841000.00
TCBIO income_statement (annual, 2024-12-31) — Reconciled Depreciation: 54228000.00
TCBIO cash_flow (annual, 2024-12-31) — Repayment Of Debt: -200000000.00
TCBIO cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -81508000.00
TCBIO balance_sheet (annual, 2024-12-31) — Retained Earnings: 2495651000.00
TCBIO income_statement (annual, 2024-12-31) — Salaries And Wages: 466578000.00
TCBIO cash_flow (annual, 2024-12-31) — Sale Of Business: 0.00
TCBIO cash_flow (annual, 2024-12-31) — Sale Of Investment: 1768877000.00
TCBIO income_statement (annual, 2024-12-31) — Selling And Marketing Expense: 22349000.00
TCBIO income_statement (annual, 2024-12-31) — Selling General And Administration: 512278000.00
TCBIO balance_sheet (annual, 2024-12-31) — Share Issued: 51520315.00
TCBIO income_statement (annual, 2024-12-31) — Special Income Charges: 0.00
TCBIO cash_flow (annual, 2024-12-31) — Stock Based Compensation: 24693000.00
TCBIO balance_sheet (annual, 2024-12-31) — Stockholders Equity: 3367936000.00
TCBIO balance_sheet (annual, 2024-12-31) — Tangible Book Value: 3066440000.00
TCBIO income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
TCBIO income_statement (annual, 2024-12-31) — Tax Provision: 29553000.00
TCBIO income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.28
TCBIO balance_sheet (annual, 2024-12-31) — Total Assets: 30731883000.00
TCBIO balance_sheet (annual, 2024-12-31) — Total Capitalization: 4028282000.00
TCBIO balance_sheet (annual, 2024-12-31) — Total Debt: 1545346000.00
TCBIO balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 3367936000.00
TCBIO balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 27363947000.00
TCBIO income_statement (annual, 2024-12-31) — Total Unusual Items: 0.00
TCBIO income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
TCBIO balance_sheet (annual, 2024-12-31) — Trading Securities: 0.00
TCBIO balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 5286503.00
TCBIO balance_sheet (annual, 2024-12-31) — Treasury Stock: 301842000.00
TCBIO income_statement (quarterly, 2025-03-31) — +Total Revenue: 280478000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 25270000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 1060028000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 3469958000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 3188808000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -2416000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Capital Stock: 300517000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 3802473000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Federal Funds Sold: 3802473000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Cash Dividends Paid: -4313000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Cash Financial: 201504000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: 636922000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: -23625000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 368000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Change In Account Payable: -90478000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Change In Payable: -90478000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: -90478000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Change In Receivables: 4604000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Change In Working Capital: -85874000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: 4604000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Changes In Cash: 613665000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Common Stock: 517000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 3129774000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Common Stock Payments: -31152000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Current Debt: 750000000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 750000000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 9217000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 9217000.00
TCBIO income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 42734000.00
TCBIO cash_flow (quarterly, 2025-03-31) — End Cash Position: 3802473000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: 636922000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Free Cash Flow: -2048000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Gain Loss On Investment Securities: 228000.00
TCBIO income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: 0.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -136162000.00
TCBIO income_statement (quarterly, 2025-03-31) — General And Administrative Expense: 136982000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 1496000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Held To Maturity Securities: 779354000.00
TCBIO income_statement (quarterly, 2025-03-31) — Insurance And Claims: 5341000.00
TCBIO income_statement (quarterly, 2025-03-31) — Interest Expense: 191255000.00
TCBIO income_statement (quarterly, 2025-03-31) — Interest Income: 427289000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Interest Paid Supplemental Data: 189665000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Invested Capital: 4540295000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: -23625000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 4531219000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Issuance Of Debt: 0.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 660521000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 660521000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Long Term Debt Issuance: 0.00
TCBIO cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: 0.00
TCBIO cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: -31152000.00
TCBIO income_statement (quarterly, 2025-03-31) — Net Income: 47047000.00
TCBIO income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 42734000.00
TCBIO income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 47047000.00
TCBIO income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 47047000.00
TCBIO income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 47047000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 47047000.00
TCBIO income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 47047000.00
TCBIO income_statement (quarterly, 2025-03-31) — Net Interest Income: 236034000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: -81694000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -135000000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: 0.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Net PPE: 84575000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -2416000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Net Short Term Debt Issuance: -135000000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 3428278000.00
TCBIO income_statement (quarterly, 2025-03-31) — Normalized Income: 47047000.00
TCBIO income_statement (quarterly, 2025-03-31) — Occupancy And Equipment: 10844000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 368000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Operating Gains Losses: 228000.00
TCBIO income_statement (quarterly, 2025-03-31) — Operating Revenue: 280478000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 46024933.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Other Current Borrowings: 750000000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: -136162000.00
TCBIO income_statement (quarterly, 2025-03-31) — Other Non Interest Expense: 35196000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 280099000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Payables: 25270000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 25270000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Preferred Shares Number: 300000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 300000000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Preferred Stock Dividend Paid: -4313000.00
TCBIO income_statement (quarterly, 2025-03-31) — Preferred Stock Dividends: 4313000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Preferred Stock Equity: 300000000.00
TCBIO income_statement (quarterly, 2025-03-31) — Pretax Income: 60458000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: -7048000.00
TCBIO income_statement (quarterly, 2025-03-31) — Professional Expense And Contract Services Expense: 14989000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -198597000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -2416000.00
TCBIO income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 9217000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: 0.00
TCBIO cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: -31152000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 2538385000.00
TCBIO income_statement (quarterly, 2025-03-31) — Salaries And Wages: 131641000.00
TCBIO cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 116903000.00
TCBIO income_statement (quarterly, 2025-03-31) — Selling And Marketing Expense: 5009000.00
TCBIO income_statement (quarterly, 2025-03-31) — Selling General And Administration: 141991000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Share Issued: 51707542.00
TCBIO cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 12750000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 3429774000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 3128278000.00
TCBIO income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 0.00
TCBIO income_statement (quarterly, 2025-03-31) — Tax Provision: 13411000.00
TCBIO income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.22
TCBIO balance_sheet (quarterly, 2025-03-31) — Total Assets: 31375749000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 4090295000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Total Debt: 1410521000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 3429774000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 27945975000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Trading Securities: 1808000.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 5682609.00
TCBIO balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 332994000.00
TCBIO income_statement (quarterly, 2025-06-30) — +Total Revenue: 307464000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 14120000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 1065083000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Available For Sale Securities: 3842833000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 3802473000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -5544000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Capital Stock: 300517000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 2690142000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Federal Funds Sold: 2690142000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Cash Dividends Paid: -4312000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Cash Financial: 182451000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: 445657000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -1620985000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 62997000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Change In Account Payable: 22274000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Change In Payable: 22274000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: 22274000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Change In Receivables: -71558000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Change In Working Capital: -49284000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: -71558000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Changes In Cash: -1112331000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Common Stock: 517000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 3210070000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Common Stock Payments: -21006000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Current Debt: 1250000000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 1250000000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 14452000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 14452000.00
TCBIO income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 73016000.00
TCBIO cash_flow (quarterly, 2025-06-30) — End Cash Position: 2690142000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: 445657000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 57453000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Gain Loss On Investment Securities: -4012000.00
TCBIO income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: -1886000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -112931000.00
TCBIO income_statement (quarterly, 2025-06-30) — General And Administrative Expense: 125250000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 1496000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Held To Maturity Securities: 761907000.00
TCBIO income_statement (quarterly, 2025-06-30) — Insurance And Claims: 5096000.00
TCBIO income_statement (quarterly, 2025-06-30) — Interest Expense: 186172000.00
TCBIO income_statement (quarterly, 2025-06-30) — Interest Income: 439567000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Interest Paid Supplemental Data: 197322000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Invested Capital: 5080326000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -1620985000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 4608628000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 620256000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 620256000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -40435000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: -21006000.00
TCBIO income_statement (quarterly, 2025-06-30) — Net Income: 77328000.00
TCBIO income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 73016000.00
TCBIO income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 77328000.00
TCBIO income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 77328000.00
TCBIO income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 77328000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 77328000.00
TCBIO income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 77328000.00
TCBIO income_statement (quarterly, 2025-06-30) — Net Interest Income: 253395000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: -56726000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: 459565000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -40435000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Net PPE: 86831000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -5544000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Net Short Term Debt Issuance: 500000000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 3508574000.00
TCBIO income_statement (quarterly, 2025-06-30) — Normalized Income: 77328000.00
TCBIO income_statement (quarterly, 2025-06-30) — Occupancy And Equipment: 12144000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 62997000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Operating Gains Losses: -2126000.00
TCBIO income_statement (quarterly, 2025-06-30) — Operating Revenue: 307464000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 45746836.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Other Current Borrowings: 1250000000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -112931000.00
TCBIO income_statement (quarterly, 2025-06-30) — Other Non Interest Expense: 38189000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 0.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Payables: 14120000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 14120000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Preferred Shares Number: 300000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 300000000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Preferred Stock Dividend Paid: -4312000.00
TCBIO income_statement (quarterly, 2025-06-30) — Preferred Stock Dividends: 4312000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Preferred Stock Equity: 300000000.00
TCBIO income_statement (quarterly, 2025-06-30) — Pretax Income: 102188000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 135000.00
TCBIO income_statement (quarterly, 2025-06-30) — Professional Expense And Contract Services Expense: 11069000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -501455000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -5544000.00
TCBIO income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 14452000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -40435000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: -21006000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Retained Earnings: 2611401000.00
TCBIO income_statement (quarterly, 2025-06-30) — Salaries And Wages: 120154000.00
TCBIO cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 444729000.00
TCBIO income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 3624000.00
TCBIO income_statement (quarterly, 2025-06-30) — Selling General And Administration: 128874000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Share Issued: 51747305.00
TCBIO cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 7627000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 3510070000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 3208574000.00
TCBIO income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
TCBIO income_statement (quarterly, 2025-06-30) — Tax Provision: 24860000.00
TCBIO income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.24
TCBIO balance_sheet (quarterly, 2025-06-30) — Total Assets: 31943535000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 4130326000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Total Debt: 1870256000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 3510070000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 28433465000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Trading Securities: 3888000.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 6000469.00
TCBIO balance_sheet (quarterly, 2025-06-30) — Treasury Stock: 354000000.00
TCBIO income_statement (quarterly, 2025-09-30) — +Total Revenue: 340354000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 9360000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 1069582000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Available For Sale Securities: 55054000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 2690142000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -4950000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Capital Stock: 300518000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 3064825000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Federal Funds Sold: 3064825000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Cash Dividends Paid: -4313000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Cash Financial: 212438000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: 454054000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -245666000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 166295000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Change In Account Payable: 1921000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Change In Payable: 1921000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 1921000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Change In Receivables: 27005000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 28926000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: 27005000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Changes In Cash: 374683000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Common Stock: 518000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 3337098000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -7076000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Current Debt: 0.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 0.00
TCBIO cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 12622000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 12622000.00
TCBIO income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: 100897000.00
TCBIO cash_flow (quarterly, 2025-09-30) — End Cash Position: 3064825000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: 454054000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 161345000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Gain Loss On Investment Securities: -700000.00
TCBIO income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: 0.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -84224000.00
TCBIO income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 125054000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 1496000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Held To Maturity Securities: 743120000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Income Tax Paid Supplemental Data: 14589000.00
TCBIO income_statement (quarterly, 2025-09-30) — Insurance And Claims: 5198000.00
TCBIO income_statement (quarterly, 2025-09-30) — Interest Expense: 188844000.00
TCBIO income_statement (quarterly, 2025-09-30) — Interest Income: 460615000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Interest Paid Supplemental Data: 193604000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Invested Capital: 3957514000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -245666000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 4601654000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 620416000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 620416000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: 0.00
TCBIO cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -7076000.00
TCBIO income_statement (quarterly, 2025-09-30) — Net Income: 105210000.00
TCBIO income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: 100897000.00
TCBIO income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: 105210000.00
TCBIO income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: 105210000.00
TCBIO income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: 105210000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: 105210000.00
TCBIO income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: 105210000.00
TCBIO income_statement (quarterly, 2025-09-30) — Net Interest Income: 271771000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Net Investment Purchase And Sale: 39353000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -975000000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: 0.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Net PPE: 88348000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Net PPE Purchase And Sale: -4950000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Net Short Term Debt Issuance: -975000000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 3635602000.00
TCBIO income_statement (quarterly, 2025-09-30) — Normalized Income: 105210000.00
TCBIO income_statement (quarterly, 2025-09-30) — Occupancy And Equipment: 11828000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: 166295000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: -700000.00
TCBIO income_statement (quarterly, 2025-09-30) — Operating Revenue: 340354000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 45679863.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Other Current Borrowings: 0.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Other Equity Adjustments: -84224000.00
TCBIO income_statement (quarterly, 2025-09-30) — Other Non Interest Expense: 37807000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Other Short Term Investments: 3801261000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Payables: 9360000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 9360000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Preferred Shares Number: 300000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Preferred Stock: 300000000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Preferred Stock Dividend Paid: -4313000.00
TCBIO income_statement (quarterly, 2025-09-30) — Preferred Stock Dividends: 4313000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Preferred Stock Equity: 300000000.00
TCBIO income_statement (quarterly, 2025-09-30) — Pretax Income: 137779000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: -646000.00
TCBIO income_statement (quarterly, 2025-09-30) — Professional Expense And Contract Services Expense: 12474000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Purchase Of Investment: -143138000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Purchase Of PPE: -4950000.00
TCBIO income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 12622000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: 0.00
TCBIO cash_flow (quarterly, 2025-09-30) — Repurchase Of Capital Stock: -7076000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Retained Earnings: 2712298000.00
TCBIO income_statement (quarterly, 2025-09-30) — Salaries And Wages: 119856000.00
TCBIO cash_flow (quarterly, 2025-09-30) — Sale Of Investment: 182491000.00
TCBIO income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 3412000.00
TCBIO income_statement (quarterly, 2025-09-30) — Selling General And Administration: 128466000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Share Issued: 51767419.00
TCBIO cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 8237000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 3637098000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 3335602000.00
TCBIO income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
TCBIO income_statement (quarterly, 2025-09-30) — Tax Provision: 32569000.00
TCBIO income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.24
TCBIO balance_sheet (quarterly, 2025-09-30) — Total Assets: 32536980000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 4257514000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Total Debt: 620416000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 3637098000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 28899882000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Trading Securities: 2219000.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Treasury Shares Number: 6087556.00
TCBIO balance_sheet (quarterly, 2025-09-30) — Treasury Stock: 361076000.00
TCBIO income_statement (annual, 2025-12-31) — +Total Revenue: 1255779000.00
TCBIO income_statement (quarterly, 2025-12-31) — +Total Revenue: 327483000.00
TCBIO balance_sheet (annual, 2025-12-31) — Accounts Payable: 6716000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 6716000.00
TCBIO balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -43685000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -43685000.00
TCBIO balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 1074496000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 1074496000.00
TCBIO balance_sheet (annual, 2025-12-31) — Available For Sale Securities: 3993453000.00
TCBIO balance_sheet (quarterly, 2025-12-31) — Available For Sale Securities: 3993453000.00
TCBIO cash_flow (annual, 2025-12-31) — Beginning Cash Position: 3188808000.00
TCBIO cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 3064825000.00
TCBIO cash_flow (annual, 2025-12-31) — Capital Expenditure: -12569000.00